Previous 10 | Next 10 |
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19, dry eye disease (DED) and Cancer, today ann...
SAN DIEGO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease di...
SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and cancer, announc...
AXIM Biotechnologies ([[AXIM]]) has completed pre-clinical drug studies on its SPX-1009 compound, demonstrating the suppression of malignant metastatic melanoma cells.The company intends to initiate animal studies to demonstrate the ability of SPX-1009 to suppress tumor growth and m...
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- AXIM ® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting onc...
SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced ...
SAN DIEGO, May 03, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc . (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced...
SAN DIEGO, March 24, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announce...
AXIM Biotechnologies (AXIM) has completed point-of-care clinical trials on its ImmunoPass rapid test that semi-quantitatively measures levels of COVID-19 neutralizing antibodies.The test aims to help understand COVID-19 immunity, validate vaccine’s effectiveness and estimate how l...
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announce...
News, Short Squeeze, Breakout and More Instantly...
Axim Biotechnologies Inc Company Name:
AXIM Stock Symbol:
OTCMKTS Market:
Axim Biotechnologies Inc Website:
State of California Department of Public Heath Food and Drug Branch Issues the Company a License for Manufacturing of its Diagnostic Assays SAN DIEGO, CA - ( NewMediaWire ) - May 29, 2024 - AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” ...
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM’s Diagnostic Research Programs in Dry Eye Disease and Parkinson’s SAN DIEGO, CA - ( NewMediaWire ) - March 27, 2024 - AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,...
The Company’s Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM’s Digital Assay Reader SAN DIEGO, CA - ( NewMediaWire ) - February 20, 2024 - AXIM Biotechnologies, Inc . ( OTCQB: AXIM ) (“AXIM Biotech,” ...